Money20/20, the world’s leading fintech show, and the place where money does business, hosted its Policy Exchange on June 3rd at Money20/20 Europe at the RAI in Amsterdam. Money20/20 Europe's Policy Exchange convened senior leaders from central banks, regulatory bodies, and industry to address three critical areas: post-MiCA crypto regulation, financial data access through Open Finance, and cross-border policy in collaboration with BIS. The exclusive closed-door ...

Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full re...

Visa Cash App Racing Bulls Formula One™ Team has deployed Neural Concept, the world’s leading AI platform for engineering design to accelerate the team’s car design and optimize aerodynamic performance through AI-powered, data-driven engineering workflows that enable faster design iteration and better-informed decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603592297/en/ ...

Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: h...

Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, th...